Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 10/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.55 |
| ▸ | HPGD | P15428 | 5/20 | 0.55 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.55 |
| ▸ | SIRT2 | Q8IXJ6 | 4/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.46 |
| ▸ | POLB | P06746 | 2/20 | 0.46 |
| ▸ | PDCD1 | Q15116 | 1/20 | 0.46 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.45 |
| ▸ | MAPT | P10636 | 2/20 | 0.45 |
| ▸ | MEN1 | O00255 | 2/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | NPC1 | O15118 | 2/20 | 0.45 |
| ▸ | RAB9A | P51151 | 2/20 | 0.45 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.45 |
| ▸ | TP53 | P04637 | 1/20 | 0.45 |
| ▸ | PKM | P14618 | 1/20 | 0.45 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.45 |
| ▸ | CASP1 | P29466 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Benzene SCHEMBL28257697 | 0.98 | KDM4E (0.54) | KDM4EALDH1A1HPGDHSD17B10SIRT2 | |
| SCHEMBL10636097 | 0.85 | KDM4E (0.55) | KDM4EALDH1A1HPGDHSD17B10SIRT2 | |
| SCHEMBL1127360 | 0.83 | KMT2A (0.65) | KDM4EALDH1A1HPGDHSD17B10SIRT2 | |
| SCHEMBL2567219 | 0.82 | ALDH1A1 (0.55) | KDM4EALDH1A1HPGDHSD17B10POLB | |
| SCHEMBL11017105 | 0.81 | CA1 (0.54) | KDM4EALDH1A1HPGDHSD17B10SMN1; SMN2 | |
| SCHEMBL5798626 | 0.81 | KMT2A (0.45) | KDM4EALDH1A1HPGDHSD17B10SMN1; SMN2 | |
| SCHEMBL3416851 | 0.80 | KDM4E (0.60) | KDM4EALDH1A1HPGDSMN1; SMN2POLB | |
| SCHEMBL22638691 | 0.80 | KDM4E (0.62) | KDM4EALDH1A1HPGDHSD17B10SIRT2 | |
| SCHEMBL30600495 | 0.79 | KDM4E (0.50) | KDM4EALDH1A1HPGDHSD17B10SIRT2 | |
| SCHEMBL3353838 | 0.79 | CA2 (0.57) | KDM4EALDH1A1HPGDHSD17B10SIRT2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11254720-B2 | Methods and systems for designing and/or characterizing soluble lipidated ligand agents | ON TARGET THERAPEUTICS LLC (US) | 2022-02-22 | — | — | US | disclosed |
| US-20190135882-A1 | Methods and Systems for Designing and/or Characterizing Soluble Lipidated Ligand Agents | ON TARGET THERAPEUTICS LLC | 2019-05-09 | — | — | US | disclosed |
| CN-104023724-A | N-THIO-ANTHRANILAMIDE COMPOUNDS AND THEIR USE AS PESTICIDES | BASF SE | 2014-09-03 | — | — | CN | disclosed |
| EP-2210597-A2 | Bacterial virulence modifying agents | Creative Antibiotics Sweden AB (SE) | 2010-07-28 | — | — | EP | disclosed |
| US-7351861-B2 | Method and probe for identifying bacterial virulence modifying agents, agents thus identified, and their use | INNATE PHARMACEUTICALS AB (SE) | 2008-04-01 | — | — | US | disclosed |
| US-20060134724-A1 | Method and probe for identifying bacterial virulence modifying agents, agents thus identifed, and their use | CHARLOTTA SUNDIN (SE) | 2006-06-22 | — | — | US | disclosed |
| EP-1543148-A1 | METHOD AND PROBE FOR IDENTIFYING BACTERIAL VIRULENCE MODIFYING AGENTS, AGENTS THUS IDENTIFIED, AND THEIR USE | Innate Pharmaceuticals AB (SE) | 2005-06-22 | — | — | EP | disclosed |
| WO-2004022775-A1 | METHOD AND PROBE FOR IDENTIFYING BACTERIAL VIRULENCE MODIFYING AGENTS, AGENTS THUS IDENTIFIED, AND THEIR USE | INNATE PHARMACEUTICALS AB (SE) | 2004-03-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11254720-B2 | Methods and systems for designing and/or characterizing soluble lipidated ligand agents | LDLR, HDLBP, LIPG | KDM4E 4313/4885ALDH1A1 3084/4885HPGD 2521/4885 |
| US-20190135882-A1 | Methods and Systems for Designing and/or Characterizing Soluble Lipidated Ligand Agents | LDLR, HDLBP, LIPG | KDM4E 4313/4885ALDH1A1 3084/4885HPGD 2521/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.